209 related articles for article (PubMed ID: 32152081)
1. Adduct Formation of Delamanid with NAD in Mycobacteria.
Hayashi M; Nishiyama A; Kitamoto R; Tateishi Y; Osada-Oka M; Nishiuchi Y; Kaboso SA; Chen X; Fujiwara M; Inoue Y; Kawano Y; Kawasaki M; Abe T; Sato T; Kaneko K; Itoh K; Matsumoto S; Matsumoto M
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32152081
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of resistance to delamanid, a drug for Mycobacterium tuberculosis.
Fujiwara M; Kawasaki M; Hariguchi N; Liu Y; Matsumoto M
Tuberculosis (Edinb); 2018 Jan; 108():186-194. PubMed ID: 29523322
[TBL] [Abstract][Full Text] [Related]
3. Genetic diversity of candidate loci linked to Mycobacterium tuberculosis resistance to bedaquiline, delamanid and pretomanid.
Gómez-González PJ; Perdigao J; Gomes P; Puyen ZM; Santos-Lazaro D; Napier G; Hibberd ML; Viveiros M; Portugal I; Campino S; Phelan JE; Clark TG
Sci Rep; 2021 Sep; 11(1):19431. PubMed ID: 34593898
[TBL] [Abstract][Full Text] [Related]
4. Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB).
Liu Y; Matsumoto M; Ishida H; Ohguro K; Yoshitake M; Gupta R; Geiter L; Hafkin J
Tuberculosis (Edinb); 2018 Jul; 111():20-30. PubMed ID: 30029909
[TBL] [Abstract][Full Text] [Related]
5. Delamanid when other anti-tuberculosis-treatment regimens failed due to resistance or tolerability.
Kwon YS; Jeong BH; Koh WJ
Expert Opin Pharmacother; 2015 Feb; 16(2):253-61. PubMed ID: 25327169
[TBL] [Abstract][Full Text] [Related]
6. The
Mansjö M; Karlsson Lindsjö O; Grönfors Seeth C; Groenheit R; Werngren J
Antimicrob Agents Chemother; 2022 Dec; 66(12):e0102622. PubMed ID: 36409105
[TBL] [Abstract][Full Text] [Related]
7. Spontaneous Mutational Patterns and Novel Mutations for Delamanid Resistance in Mycobacterium tuberculosis.
Liu Y; Shi J; Li L; Wu T; Chu P; Pang Y; Guo Y; Gao M; Lu J
Antimicrob Agents Chemother; 2022 Dec; 66(12):e0053122. PubMed ID: 36448833
[TBL] [Abstract][Full Text] [Related]
8. Multidrug Resistant Tuberculosis With Simultaneously Acquired Drug Resistance to Bedaquiline and Delamanid.
Yoshiyama T; Takaki A; Aono A; Mitarai S; Okumura M; Ohta K; Kato S
Clin Infect Dis; 2021 Dec; 73(12):2329-2331. PubMed ID: 32730621
[TBL] [Abstract][Full Text] [Related]
9. Comparison of in vitro activity of the nitroimidazoles delamanid and pretomanid against multidrug-resistant and extensively drug-resistant tuberculosis.
Wen S; Jing W; Zhang T; Zong Z; Xue Y; Shang Y; Wang F; Huang H; Chu N; Pang Y
Eur J Clin Microbiol Infect Dis; 2019 Jul; 38(7):1293-1296. PubMed ID: 30953211
[TBL] [Abstract][Full Text] [Related]
10. Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea.
Yang JS; Kim KJ; Choi H; Lee SH
Ann Lab Med; 2018 Nov; 38(6):563-568. PubMed ID: 30027700
[TBL] [Abstract][Full Text] [Related]
11. Characterization of Genomic Variants Associated with Resistance to Bedaquiline and Delamanid in Naive Mycobacterium tuberculosis Clinical Strains.
Battaglia S; Spitaleri A; Cabibbe AM; Meehan CJ; Utpatel C; Ismail N; Tahseen S; Skrahina A; Alikhanova N; Mostofa Kamal SM; Barbova A; Niemann S; Groenheit R; Dean AS; Zignol M; Rigouts L; Cirillo DM
J Clin Microbiol; 2020 Oct; 58(11):. PubMed ID: 32907992
[TBL] [Abstract][Full Text] [Related]
12. Genotypic Analysis of Genes Associated with Independent Resistance and Cross-Resistance to Isoniazid and Ethionamide in Mycobacterium tuberculosis Clinical Isolates.
Rueda J; Realpe T; Mejia GI; Zapata E; Rozo JC; Ferro BE; Robledo J
Antimicrob Agents Chemother; 2015 Dec; 59(12):7805-10. PubMed ID: 26369965
[TBL] [Abstract][Full Text] [Related]
13. Loss-of-function mutations in
Pandey S; Vilchèze C; Werngren J; Bainomugisa A; Mansjö M; Groenheit R; Miotto P; Cirillo DM; Coulter C; Baulard AR; Schön T; Jacobs WR; Djaout K; Köser CU
Antimicrob Agents Chemother; 2024 Jan; 68(1):e0109623. PubMed ID: 38038476
[TBL] [Abstract][Full Text] [Related]
14. A novel metabolite of antituberculosis therapy demonstrates host activation of isoniazid and formation of the isoniazid-NAD+ adduct.
Mahapatra S; Woolhiser LK; Lenaerts AJ; Johnson JL; Eisenach KD; Joloba ML; Boom WH; Belisle JT
Antimicrob Agents Chemother; 2012 Jan; 56(1):28-35. PubMed ID: 22037847
[TBL] [Abstract][Full Text] [Related]
15. The Activities and Secretion of Cytokines Caused by Delamanid on Macrophages Infected by Multidrug-Resistant
Lyu XL; Lin TT; Gao JT; Jia HY; Zhu CZ; Li ZH; Dong J; Sun Q; Shu W; Pan LP; Zhang ZD; Li Q
Front Immunol; 2021; 12():796677. PubMed ID: 35003120
[TBL] [Abstract][Full Text] [Related]
16. Delamanid Central Nervous System Pharmacokinetics in Tuberculous Meningitis in Rabbits and Humans.
Tucker EW; Pieterse L; Zimmerman MD; Udwadia ZF; Peloquin CA; Gler MT; Ganatra S; Tornheim JA; Chawla P; Caoili JC; Ritchie B; Jain SK; Dartois V; Dooley KE
Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31383662
[TBL] [Abstract][Full Text] [Related]
17. Coenzyme F
Purwantini E; Loganathan U; Mukhopadhyay B
J Bacteriol; 2018 Dec; 200(23):. PubMed ID: 30249701
[TBL] [Abstract][Full Text] [Related]
18. Delamanid: first global approval.
Ryan NJ; Lo JH
Drugs; 2014 Jun; 74(9):1041-5. PubMed ID: 24923253
[TBL] [Abstract][Full Text] [Related]
19. Delamanid for the treatment of pulmonary multidrug-resistant tuberculosis.
Thakare R; Soni I; Dasgupta A; Chopra S
Drugs Today (Barc); 2015 Feb; 51(2):117-23. PubMed ID: 25756067
[TBL] [Abstract][Full Text] [Related]
20. Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis.
Rozwarski DA; Grant GA; Barton DH; Jacobs WR; Sacchettini JC
Science; 1998 Jan; 279(5347):98-102. PubMed ID: 9417034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
